Display options
Cite
Refaie MM, Amin EF, El-Tahawy NF, et al. Possible Protective Effect of Diacerein on Doxorubicin-Induced Nephrotoxicity in Rats. J Toxicol. 2016;2016:9507563doi: 10.1155/2016/9507563.
Refaie, M. M., Amin, E. F., El-Tahawy, N. F., & Abdelrahman, A. M. (2016). Possible Protective Effect of Diacerein on Doxorubicin-Induced Nephrotoxicity in Rats. Journal of toxicology, 20169507563. https://doi.org/10.1155/2016/9507563
Refaie, Marwa M M, et al. "Possible Protective Effect of Diacerein on Doxorubicin-Induced Nephrotoxicity in Rats." Journal of toxicology vol. 2016 (2016): 9507563. doi: https://doi.org/10.1155/2016/9507563
Refaie MM, Amin EF, El-Tahawy NF, Abdelrahman AM. Possible Protective Effect of Diacerein on Doxorubicin-Induced Nephrotoxicity in Rats. J Toxicol. 2016;2016:9507563. doi: 10.1155/2016/9507563. Epub 2016 Jan 20. PMID: 26904117; PMCID: PMC4745331.
Copy Download .nbib Format: NLM
Share it on

J Toxicol. 2016;2016:9507563. doi: 10.1155/2016/9507563. Epub 2016 Jan 20.

Possible Protective Effect of Diacerein on Doxorubicin-Induced Nephrotoxicity in Rats.

Journal of toxicology

Marwa M M Refaie, Entesar F Amin, Nashwa F El-Tahawy, Aly M Abdelrahman

Affiliations

  1. Department of Pharmacology, Faculty of Medicine, El-Minia University, El-Minia 61111, Egypt.
  2. Department of Histology, Faculty of Medicine, El-Minia University, El-Minia 61111, Egypt.

PMID: 26904117 PMCID: PMC4745331 DOI: 10.1155/2016/9507563

Abstract

Nephrotoxicity is one of the limiting factors for using doxorubicin (DOX). Interleukin 1 has major role in DOX-induced nephrotoxicity, so we investigated the effect of interleukin 1 receptor antagonist diacerein (DIA) on DOX-induced nephrotoxicity. DIA (25 and 50 mg/kg/day) was administered orally to rats for 15 days, in the presence or absence of nephrotoxicity induced by a single intraperitoneal injection of DOX (15 mg/kg) at the 11th day. We measured levels of serum urea, creatinine, renal reduced glutathione (GSH), malondialdehyde (MDA), total nitrites (NO x ), catalase, and superoxide dismutase (SOD). In addition, caspase-3, tumor necrosis factor alpha (TNFα), nuclear factor kappa B (NFκB) expressions, and renal histopathology were assessed. Our results showed that DOX-induced nephrotoxicity was ameliorated or reduced by both doses of DIA, but diacerein high dose (DHD) showed more improvement than diacerein low dose (DLD). This protective effect was manifested by significant improvement in all measured parameters compared to DOX treated group by using DHD. DLD showed significant improvement of creatinine, MDA, NO x , GSH, histopathology, and immunohistochemical parameters compared to DOX treated group.

References

  1. Zhonghua Yi Xue Za Zhi. 2005 Jul 13;85(26):1836-41 - PubMed
  2. J Lab Clin Med. 1963 May;61:882-8 - PubMed
  3. Curr Med Chem. 2009;16(25):3267-85 - PubMed
  4. Clin Chim Acta. 2004 Oct;348(1-2):27-34 - PubMed
  5. J Egypt Natl Canc Inst. 2005 Dec;17(4):291-300 - PubMed
  6. FEBS Lett. 2004 Nov 19;577(3):483-90 - PubMed
  7. Evid Based Complement Alternat Med. 2015;2015:357357 - PubMed
  8. Biopharm Drug Dispos. 1997 Dec;18(9):769-77 - PubMed
  9. Toxicol Mech Methods. 2013 Jun;23(5):337-45 - PubMed
  10. Am J Pathol. 1978 Oct;93(1):137-52 - PubMed
  11. Pharmacol Rep. 2008 Sep-Oct;60(5):742-9 - PubMed
  12. Adv Pharmacol Sci. 2013;2013:387071 - PubMed
  13. Nature. 1985 Feb 28-Mar 6;313(6005):803-6 - PubMed
  14. Methods Enzymol. 1984;105:121-6 - PubMed
  15. Pharmacology. 2001;63(4):228-33 - PubMed
  16. Toxicology. 2004 Sep 1;201(1-3):173-84 - PubMed
  17. Ann Biol Clin (Paris). 1999 Nov-Dec;57(6):685-95 - PubMed
  18. Biopharm Drug Dispos. 1991 May;12(4):251-9 - PubMed
  19. Food Chem Toxicol. 2010 Jan;48(1):436-40 - PubMed
  20. Food Chem Toxicol. 2008 Sep;46(9):3178-81 - PubMed
  21. Am J Clin Nutr. 2006 Feb;83(2):447S-455S - PubMed
  22. Pharmacogenet Genomics. 2011 Jul;21(7):440-6 - PubMed
  23. Naunyn Schmiedebergs Arch Pharmacol. 2011 Mar;383(3):309-19 - PubMed
  24. PLoS One. 2015 Mar 27;10(3):e0121842 - PubMed
  25. Biochem Biophys Res Commun. 1972 Jan 31;46(2):849-54 - PubMed
  26. Ther Adv Musculoskelet Dis. 2010 Apr;2(2):95-104 - PubMed
  27. Pharmacol Biochem Behav. 2012 Oct;102(4):549-54 - PubMed
  28. Acta Pharmacol Sin. 2013 Apr;34(4):515-21 - PubMed
  29. J Rheumatol. 1998 Dec;25(12):2417-24 - PubMed
  30. Cancer Epidemiol Biomarkers Prev. 2010 Apr;19(4):1089-97 - PubMed
  31. Clin Chim Acta. 2003 May;331(1-2):111-7 - PubMed
  32. Int J Nephrol. 2012;2012:465897 - PubMed
  33. Sci Rep. 2015 Jul 07;5:11822 - PubMed
  34. Chem Pharm Bull (Tokyo). 1983 Feb;31(2):605-11 - PubMed
  35. Clin Chem. 1975 Apr;21(5):1D-432D - PubMed
  36. Adv Pharmacol Sci. 2012;2012:981461 - PubMed
  37. Planta Med. 2015 Mar;81(4):279-85 - PubMed

Publication Types